Adaptimmune Therapeutics PLC (ADAP)
1.125
+0.12
(+11.39%)
USD |
NASDAQ |
Apr 23, 16:00
1.15
+0.02
(+2.22%)
After-Hours: 20:00
Adaptimmune Therapeutics Free Cash Flow: -145.76M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -145.76M |
| September 30, 2023 | -131.64M |
| June 30, 2023 | -144.59M |
| March 31, 2023 | -149.80M |
| December 31, 2022 | -171.51M |
| September 30, 2022 | -40.24M |
| June 30, 2022 | -28.71M |
| March 31, 2022 | -11.74M |
| December 31, 2021 | 1.948M |
| September 30, 2021 | -158.39M |
| June 30, 2021 | -128.64M |
| March 31, 2021 | -120.84M |
| December 31, 2020 | -56.50M |
| September 30, 2020 | -39.19M |
| June 30, 2020 | -52.01M |
| March 31, 2020 | -61.76M |
| Date | Value |
|---|---|
| December 31, 2019 | -115.58M |
| September 30, 2019 | -134.34M |
| June 30, 2019 | -95.80M |
| March 31, 2019 | -97.22M |
| December 31, 2018 | -109.10M |
| September 30, 2018 | -100.48M |
| June 30, 2018 | -97.22M |
| March 31, 2018 | -87.59M |
| December 31, 2017 | -79.33M |
| September 30, 2017 | -60.59M |
| June 30, 2017 | -89.91M |
| March 31, 2017 | -80.64M |
| December 31, 2016 | -60.95M |
| September 30, 2016 | -63.53M |
| June 30, 2016 | -49.49M |
| March 31, 2016 | -45.42M |
Free Cash Flow Range, Past 5 Years
-171.51M
Minimum
Dec 2022
1.948M
Maximum
Dec 2021
-93.95M
Average
-115.58M
Median
Dec 2019
Free Cash Flow Benchmarks
| Biodexa Pharmaceuticals Plc | -8.842M |
| NuCana PLC | -33.49M |
| Autolus Therapeutics PLC | -156.57M |
| Mereo BioPharma Group PLC | -21.55M |
| TC BioPharm (Holdings) PLC | -13.42M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -14.68M |
| Cash from Investing (Quarterly) | 68.20M |
| Cash from Financing (Quarterly) | 0.074M |
| Free Cash Flow Per Share (Quarterly) | -0.0682 |
| Free Cash Flow to Equity (Quarterly) | -15.50M |
| Free Cash Flow to Firm (Quarterly) | -15.50M |
| Free Cash Flow Yield | -64.37% |